Bristol-Myers Squibb Company
BMY#126 of 134 by buybacksNYSE · Healthcare · Drug Manufacturers - General · USA
bms.comBuybacks · FY2025$0latest fiscal year
Buyback yield0.0%repurchases ÷ market cap
Dividends · FY2025$5.04Bdividend yield 4.2%
Shareholder yield4.2%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−7.7%2.05B shares (2026)
Buybacks ÷ free cash flow0%payout incl. dividends 39%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $0 | $5.04B | $12.8B |
| FY2024Dec 2024 | $0 | $4.86B | $13.9B |
| FY2023Dec 2023 | $5.16B | $4.74B | $12.7B |
| FY2022Dec 2022 | $8.00B | $4.63B | $11.9B |
| FY2021Dec 2021 | $6.29B | $4.40B | $15.2B |
| FY2020Dec 2020 | $1.55B | $4.08B | $13.3B |
| FY2019Dec 2019 | $7.30B | $2.68B | $7.23B |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to t…
- Market cap
- $121B
- P/E (trailing)
- 13.0×
- Fiscal year end
- December
- ISIN
- US1101221083
- Reporting currency
- USD
- Data updated
- Oct 9, 2026